Hostname: page-component-848d4c4894-x24gv Total loading time: 0 Render date: 2024-05-16T21:51:14.235Z Has data issue: false hasContentIssue false
  • English
  • Français

Management of sedation due to clozapine

Published online by Cambridge University Press:  16 May 2022

Sumeet Gupta Open the ORCID record for Sumeet Gupta [Opens in a new window]  and
Samuel Mammolotti Parkinson
Sumeet Gupta*
Affiliation:
A consultant psychiatrist in a community mental health team in Tees, Esk and Wear Valleys NHS Foundation Trust (TEWV), Harrogate, UK. His research interests include management of affective disorder and adverse effects of psychotropic drugs, evidence-based medicine and clinical trials of psychotropic drugs.
Samuel Mammolotti Parkinson
Affiliation:
A higher trainee in general adult psychiatry currently working on a female acute in-patient ward at Foss Park Hospital, York, UK. He is undertaking special interest sessions in psychotherapy and clinical research.
*
Correspondence Dr Sumeet Gupta. Email: sumeet.gupta@nhs.net
Get access Rights & Permissions [Opens in a new window]

Summary

Sedation is one of the most common adverse effects of clozapine. Although tolerance develops to some extent, a significant proportion of patients continue to experience sedation and associated negative consequences on their quality of life. Sedation is also one of the most common reasons for the discontinuation of clozapine and it is therefore important to proactively manage it. This article provides brief guidance for clinicians.

Keywords

Clozapineadverse effectssedationdrug interactions and side-effectsantipsychotics
Type
Refreshment
Information
BJPsych Advances , Volume 29 , Issue 4 , July 2023 , pp. 283 - 284
Check for updates
Copyright
Copyright © The Author(s), 2022. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Chakrabarti, S (2021) Clozapine resistant schizophrenia: newer avenues of management. World Journal of Psychiatry, 11: 429–48.CrossRefGoogle ScholarPubMed
electronic medicines compendium (2020) Clozaril® 25mg and 100mg Tablets: UK Clozaril® Official Recommendations (Summary of Product Characteristics). emc (https://www.medicines.org.uk/emc/product/4411/smpc).Google Scholar
Gurcan, G, Hun Şenol, Ş, Anıl Yagcioglu, AE, et al. (2021) A common side effects and metabolic syndrome due to clozapine: relationship with the clinical variables and disability. Turkish Journal of Psychiatry, 32: 87–99.Google ScholarPubMed
Legge, SE, Hamshere, M, Hayes, RD, et al. (2016) Reasons for discontinuing clozapine: a cohort study of patients commencing treatment. Schizophrenia Research, 174: 113–9.CrossRefGoogle ScholarPubMed
Meyer, JM, Stahl, SM (2020) The Clozapine Handbook. Cambridge University Press.Google Scholar
Takeuchi, H, Powell, V, Geisler, S, et al. (2016) Clozapine administration in clinical practice: once-daily versus divided dosing. Acta Psychiatrica Scandinavica, 134: 236–40.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.